A 24-hour comparison of serum growth hormone concentrations in patients with heart failure versus healthy controls

Pharmacotherapy. 2003 Feb;23(2):147-52. doi: 10.1592/phco.23.2.147.32093.

Abstract

Study objective: To compare endogenous serum growth hormone concentrations over a 24-hour period in patients with chronic heart failure (CHF) and matched controls.

Design: Prospective, 24-hour, endogenous concentration comparison.

Setting: Hospital research center.

Patients: Eight evaluable patients with nonischemic dilated cardiomyopathy and 10 healthy control subjects, matched for age and sex.

Intervention: Over a 24-hour period, blood was drawn from the study participants every 20 minutes for determination of growth hormone.

Measurements and main results: For each patient, the area under the concentration-time curve from time 0-24 hours (AUC0-24), maximum concentration (Cmax), and minimum concentration (Cnadir) of growth hormone were determined. The AUC0-24 and Cmax were 74% (p < 0.05) and 62% (p < 0.05) lower in patients with CHF than in controls, respectively. The Cnadir for all participants was 0 microg/L. Variability in growth hormone concentrations over the 24 hours was considerable for all study participants.

Conclusions: Growth hormone concentrations are suppressed over a 24-hour period in patients with CHF versus healthy controls. Variability in levels throughout the day suggests that a single point evaluation cannot be used to determine deficiency or abundance of growth hormone.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Area Under Curve
  • Cardiomyopathy, Dilated / blood*
  • Case-Control Studies
  • Circadian Rhythm
  • Drug Monitoring
  • Female
  • Growth Hormone / blood*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Growth Hormone